HESTERBIO finished at ₹2,545, up 20.16% from ₹2,118, and the session stood out for much heavier activity than usual: turnover was about ₹120.3 crore versus a 20-day average near ₹5.7 crore, with volume at 4.82 lakh shares. The stock was the top gainer in the supplied tape for 2026-07-13 and sat in the Healthcare sector, Pharmaceuticals & Biotechnology industry. No direct company-specific headline or fresh event was provided alongside the price move, so the day’s advance cannot be tied to a confirmed catalyst from the supplied context. The move also needs to be read as a same-day market snapshot, not a broader trend signal, because no additional history or intraday detail was provided. Source: HESTERBIO price and turnover data.
Aurific Market Desk
Post-closeHESTERBIO jumps 20.2% on heavy turnover; no catalyst supplied
HESTERBIO led the gainers with a 20.16% rise to 2,545, while turnover surged to about ₹120.3 crore versus a 20-day average near ₹5.7 crore. No company-specific news was supplied with the move.
By the Aurific Market DeskJuly 13, 20261 min readAI-assisted
Members only
Continue reading with Aurific
This Aurific Market Desk note — the full analysis, live exhibits and desk read — is available to signed-in Aurific members. Sign in to keep reading, or request access.
Continue reading
More essays
The AI Divergence: Tech Resilience Meets a Financial Chill
A 2.33% weekly slide in the Nifty masks a profound divergence between AI-fueled IT optimism and a deepening liquidity crunch in the financial sector.
July 25, 2026
Consolidation Over Conviction: The Market’s M&A Pivot
As mid-cap momentum stalls in financial services, investors are rotating into specific corporate restructuring stories and 'Make in India' plays.
July 24, 2026